Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

M and S shares - bargain or basket case?

Article Abstract:

Marks and Spencer has seen a drop in its stock price, and this could represent an opportunity for investors. The company is cutting costs and has appointed a new chairman. The company could be attractive to a bidder, and it has a strong balance sheet. Despite these advantages, the company faces a difficult retailing environment, and there could be delays as a result from using overseas suppliers. There are still few new people at the company, which may not be especially attractive to a bidder.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


M and S

Article Abstract:

M and S has a new chairman, Luc Vandevelde, and investor confidence has been strengthened in the company. Charterhouse Securities rates the company's stocks an add, Investec Henderson Crosthwaite rates them a hold, and Merrill Lynch's rating is neutral.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Management, Retail industry, Retail trade, Retail stores, Marks and Spencer PLC
Similar abstracts:
  • Abstracts: Kinko's and Federal Express - in this case, two service providers are better than one. Internet Currency
  • Abstracts: Incentives versus standards: properties of accounting income in four East Asian countries. The effect of international institutional factors on properties of accounting earnings
  • Abstracts: Wisdom trade at a premium in stormy markets. Credibility pays. Bank of England shares the good news
  • Abstracts: London and Edinburgh hopes to fulfil its promise. Pearson. New blood breathes life into publisher
  • Abstracts: Healthy Glaxo SmithKline creates a gene giant. Glaxo faces drug blow. Glaxo SmithKline, king of kings?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.